Hainan Haiyao's wholly owned subsidiary Haikou Pharmaceutical Factory Co., Ltd. has obtained the Drug Registration Certificate for the chemical drug isavuconazonium sulfate for injection, approved and issued by the National Medical Products Administration. The company disclosed the matter in an announcement on October 9. The announcement noted that isavuconazonium is a new-generation broad-spectrum triazole antifungal agent used to treat invasive aspergillosis and invasive mucormycosis, with good prodrug water solubility, high bioavailability, and predictable linear pharmacokinetic properties. The company stated that the approval of this product will further enrich its anti-infective drug pipeline and help enhance the market competitiveness of its products. In the first half of 2026, Hainan Haiyao achieved revenue of 321 million yuan and a net loss attributable to the parent company of 212 million yuan.
Hainan Haiyao Co LtdSubsidiary received NMPA Drug Registration Certificate for isavuconazonium sulfate, enriching its anti-infective pipeline and boosting competitiveness.
Haikou Pharmaceutical Factory obtained the NMPA Drug Registration Certificate for isavuconazonium sulfate for injection.
